Navigation Links
Sangamo BioSciences Reports Second Quarter 2008 Financial Results
Date:7/23/2008

ayment of $6.0 million and the balance of the outstanding milestone payments of approximately $2.3 million. In addition, Sangamo is eligible to receive development and commercial milestone payments and royalties on product sales for any product that DAS develops, as well as 25% of any cash consideration received by DAS under such sublicenses. A webcast replay of the press conference that DAS hosted is available on Sangamo's website on the Investor page under Events and Presentations.

-- Presentation of complete 180 day follow-up data from Phase 1b study of SB-509 in subjects with diabetic neuropathy (DN). Data from the Phase 1b clinical trial were presented at the American Diabetes Association Meeting in June. The data demonstrate statistically significant improvement in quantitative sensory testing and Neuropathy Impairment Score-Lower Limbs (NIS-LL), a quantitative measure of the neurologic exam, as well as clinically relevant trends toward improvement in nerve conduction velocities. The trial was conducted in subjects with mild to moderate diabetic neuropathy over a six month period after a single administration of SB-509. SB-509 is an injectable formulation of plasmid DNA that encodes a ZFP transcription factor (ZFP TF(TM)), designed to upregulate the vascular endothelial growth factor-A (VEGF-A) gene.

-- Phase 2 clinical trial, SB-509-701 fully enrolled and expanded. A Phase 2 study of SB-509 is being undertaken in subjects with moderate to severe diabetic neuropathy with at least one "blocked nerve". In addition to the announcement of the completion of accrual of the first part of the trial, Sangamo announced plans to expand and broaden the trial to test an additional dosing regimen.

-- Data from critical limb ischemia Phase 1 trial presented at the International Society for Cellular Therapy Meeting. Sangamo's collaborators from Duke University presented data from the completed Phase 1 trial of the company's ZFP TF activator of VEGF-A for
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
2. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
3. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
4. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
5. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
6. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
7. Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors
8. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
9. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
10. Sangamo BioSciences to Present at the Cowen and Company 28th Annual Health Care Conference
11. Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Darrington, WA (PRWEB) May 17, 2013 Tooth ... 5th graders showing active signs of the disease. The World ... children and nearly 100% of adults have cavities. What are ... Research is showing a strong connection between the oral ... why is this disease so rampant, yet it is also ...
(Date:5/16/2013)... 2013 ISPE announced ... CAE, to the newly created position of Vice ... Myers will be responsible for stimulating ISPE’s revenue ... advancing the Society’s Member-led and staff-driven business model, ... refine organizational, membership and product marketing. , “Barbara ...
(Date:5/16/2013)... In late 2012, Dr. Sarah Hart, of ... in China about Appearance Medicine . Although Dr. Hart ... first trip to lecture in China, and quite a different ... home to 12 and 7 million people respectively. Interest in ... this point in time. As Dr. Hart passed through the ...
(Date:5/16/2013)... Cambridge Healthtech Institute will host its ... at the Renaissance Waterfront Hotel in Boston, MA. ... look at the current strategies and innovations for optimizing ... Leaders in the field will reveal how their work ... greater specificity and efficiency. , “In this age of ...
Breaking Biology Technology:Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2
... , ... leading biopharma executives will discuss how Earned Value Management can improve control over clinical ... Annual Meeting in San Diego. , ... Chicago, IL (PRWEB) June 11, 2009 -- ClearTrial ( www.cleartrial.com ), ...
... 11 Medivation, Inc. (Nasdaq: MDVN ) ... patient enrollment in the CONNECTION study, a six-month, confirmatory, ... in patients with mild-to-moderate Alzheimer,s disease. , ... enrolled 598 patients, exceeding the enrollment target of 525 ...
... BioStorage Technologies, Inc., a worldwide provider of long- ... cold chain logistics, announced it will participate in ... Biorepositories Conference, September 21 to 23, 2009 in ... , Biorepositories 2009 is the only U.S.-based biobanking ...
Cached Biology Technology:ClearTrial Industry Expert to Lead Session at DIA Annual Meeting on Improving Accrual and Contract Management in Clinical Trials 2Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 2Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 3Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 4BioStorage Technologies Takes Lead Sponsorship Role of 2nd Annual IIR Biorepositories Conference 2BioStorage Technologies Takes Lead Sponsorship Role of 2nd Annual IIR Biorepositories Conference 3
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) ... The Society for Developmental Biology (SDB) 72nd Annual ... These awards are meant to promote the entry ... into the mainstream of the basic science community ... at the SDB 2013 Annual Meeting. , Awards ...
(Date:5/16/2013)... MIT may someday eliminate the need for patients ... blood-sugar levels and inject themselves with insulin. , ... in the body and respond by secreting the ... of pancreatic islet cells, which are destroyed in ... of system could ensure that blood-sugar levels remain ...
(Date:5/16/2013)... SPARTANBURG, S.C. , May 16, 2013 /PRNewswire/ ... film in combination with a custom thin film ...  the highest forensic quality roll image in the ... market today. Sherlock, an Appendix F Mobile ID ... provides a 95% reduction in size and weight ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3
... indicates an increased risk for developing breast cancer can ... according to a new study featuring work from researchers ... and their colleagues. The multidisciplinary team found that ... more likely to be present in breast cancer patients ...
... AMES, Iowa Wind turbines in Midwestern farm fields ... turbine blades that generate renewable energy might also help corn ... off fungal infestations and improve their ability to extract growth-enhancing ... at the annual meeting of the American Geophysical Union, a ...
... nothing more powerful in a physician,s arsenal than early detection. ... remains a common and significant health problem in the United ... breast cancer in their lifetime and more than half of ... cure or effective therapeutic available. Using a new, powerful ...
Cached Biology News:Key information about breast cancer risk and development is found in 'junk' DNA 2Key information about breast cancer risk and development is found in 'junk' DNA 3Wind turbines may benefit crops 2Wind turbines may benefit crops 3Scientists discover powerful biomarker panel for the early detection of breast cancer 2Scientists discover powerful biomarker panel for the early detection of breast cancer 3
Hamster Serum; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels....
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
... First-Strand cDNA Labeling System - dCTP ... reactions. For the generation and purification ... are packaged together for complete cDNA ... can be used for performing labeling ...
... Cy5 Post-Labeling Reactive Dye Pack, 12 ... fluors specifically optimized for microarray labeling.Higher ... pmol reactive dye per vial, at ... use, individually dispensed, and packed in ...
Biology Products: